Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-09-05
2010-11-23
Badio, Barbara P (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C552S629000
Reexamination Certificate
active
07838516
ABSTRACT:
The invention provides 15β-substituted steroidal compounds having selective estrogen receptor activity according to Formula I:wherein,R1is H, C1-5alkyl, C1-12acyl, di-(C1-5alkyl)aminocarbonyl, (C1-5alkyl)oxycarbonyl or sulfamoyl,R2is H, C1-3alkyl, C2-3alkenyl or C2-3alkynyl, each of which may be optionally substituted with a halogen,R3is C1-2alkyl, ethenyl or ethynyl, each of which may be optionally substituted with a halogen, andR4is H or C1-12acyl.
REFERENCES:
patent: 3007946 (1961-11-01), Tyner
patent: 3049555 (1962-08-01), Tyner
patent: 3092645 (1963-06-01), Nicholson
patent: 3257429 (1966-06-01), Ringold et al.
patent: 3299108 (1967-01-01), Baran
patent: 3377366 (1968-04-01), Baran
patent: 3464979 (1969-09-01), Barton
patent: 3465010 (1969-09-01), Baran
patent: 3642992 (1972-02-01), Babcock et al.
patent: 3652606 (1972-03-01), Baran
patent: 3704253 (1972-11-01), Reinhardt et al.
patent: 3766224 (1973-10-01), Coombs
patent: 4272530 (1981-06-01), Teutsch et al.
patent: 5116830 (1992-05-01), Tanabe et al.
patent: 5686437 (1997-11-01), Labrie et al.
patent: 6541465 (2003-04-01), Loozen et al.
patent: 6677329 (2004-01-01), Loozen et al.
patent: 6780854 (2004-08-01), Loozen et al.
patent: 6989378 (2006-01-01), Leysen et al.
patent: 2005/0153949 (2005-07-01), Leysen et al.
patent: 1084261 (1960-06-01), None
patent: 2757157 (1979-06-01), None
patent: 0 145 493 (1989-03-01), None
patent: 0 613 687 (1994-09-01), None
patent: 0 798 378 (1997-10-01), None
patent: 0869132 (1998-10-01), None
patent: 0 890 989 (1962-03-01), None
patent: 1 341 601 (1973-12-01), None
patent: WO 94/18224 (1994-08-01), None
patent: WO 99/45886 (1999-09-01), None
patent: WO 00/31112 (2000-06-01), None
International Search Report, dated Jan. 23, 2006, for International Application No. PCT/EP2005/054368.
An English language abstract and a machine translation of DE1084261, 1960.
Two English language abstracts of DE2757157, 1979.
Avery et al., “Synthesis and Testing of 17αβ-hydroxy-7α-methyl-D-homoestra-4,16-dien-3-one: A Highly Potent Orally Action Androgen,” Steroids 55 (1990) 59-64.
Baggett et al., “Effects of Two Metabolites of Norethynodrel on Reproductive Performance of Female Rats,”Fertility And Sterility21, (1970) 68-72.
Becker et al. (eds)Behavior Endocrinology(1992) 82-84.
De Gooyer et. al., “Receptor profiling and endocrine interactions of tibolone,” Steroids 68 (2003) 21-30.
Fevig et al., “Estrogen Receptor Binding Tolerance of 16-Alpha-Substituted Estradiol Derivatives,”Steroids51(1988) 471-498.
González et. al., “Synthesis and Pharmacological Evaluation of 8α-Estradiol Derivatives,”Steroids40 (1982) 171-187.
Mosselman et. al., “Erβ: identification and characterization of a novel human estrogen Receptor,”FEBS Letters392 (1996) 49-53.
Solo et al., “7α-Alkyltestosterone Derivatives: Synthesis and Activity as Androgens and as Aromatase Inhibitors,” Steroids 40 (1982) 603-614.
Takikawa, H., “The Competitive action of 16β-Ethylestradiol on the Binding of Estrogen Receptor in Human Breast Cancer,”Res. Steroids7 (1977) 291-299.
Tedesco et al., “7α,11β-disubstituted estrogens: probes for the shape of the ligand binding pocket in the estrogen receptor,”Bioorganic&Medicinal Chemistry Letters7 (1997) 2919-2924.
Writing Group for the Women's Health Initiative Investigators, “Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from The Women's Health Initiative randomized controlled trial,”JAMA288 (2002) 321-333.
Dijcks Fredericus Antonius
Ederveen Antonius Gerardus Hendrikus
Loozen Hubert Jan Jozef
Badio Barbara P
Hess Susan L.
N.V. Organon
LandOfFree
15 β-substituted steroids having selective estrogenic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 15 β-substituted steroids having selective estrogenic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 15 β-substituted steroids having selective estrogenic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4192136